Magenta Therapeutics is a clinical-stage biotechnology company developing medicines for patients with autoimmune diseases, blood cancers and genetic diseases. Co. is developing a suite of antibody-drug conjugates (ADCs), for conditioning. Co.'s main conditioning product candidate, MGTA-117, is designed to specifically remove disease-causing hematopoietic stem cells and genetically mutated cells. Co.'s third ADC-based conditioning program, C300, targets T cells, a type of immune cell. Co. is also developing MGTA-145 as the standard of care for stem cell mobilization in a range of diseases, including autoimmune diseases, genetic diseases and blood cancers. The MGTA stock yearly return is shown above.
The yearly return on the MGTA stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2019 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the MGTA annual return calculation with any dividends reinvested as applicable (on ex-dates).
|